Q-omics provides the consensus-scored RNA5SP317 profile across patient tissues and cancer cell-line models. RNA5SP317 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RNA5SP317 is differentially expressed in 6, with the highest sampling consensus in STAD. Additionally, RNA5SP317 RNA expression shows 17,720 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, STAD, and THYM as cancer lineages where RNA5SP317 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNA5SP317 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNA5SP317 survival associations across molecular data types. RNA5SP317 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNA5SP317 RNA expression–survival associations across cancer types. High RNA5SP317 expression shows unfavorable associations in BLCA, KIRC and CHOL, but favorable associations in LUAD, HNSC and READ. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for RNA5SP317 RNA expression.
This table summarizes RNA5SP317 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNA5SP317. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNA5SP317 shows lower tumor expression in LUSC, BRCA and THCA and higher tumor expression in STAD, LIHC and CHOL. The STAD box plot shows higher RNA5SP317 RNA expression in tumor versus normal tissue (log2 FC = +0.775, t-test p = .016).
This table shows molecular features associated with RNA5SP317 in patient tissues and cancer cell lines. In patient samples, RNA5SP317 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
